PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor

PolyPid Ltd PYPD has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program.
OncoPLEX is designed to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy agents.
OncoPLEX induced strong inhibition of tumor growth and recurrence in a partially resected human glioblastoma subcutaneous mouse model.
A single local OncoPLEX application induced 98% tumor growth inhibition (day 41 post-operation) compared to the untreated control and 66% compared to multiple injections of systemic chemo arm.
The day 41 survival rate for OncoPLEX was much higher than the systemically treated mice or untreated with 60%, 20%, and 10% survival, respectively.
OncoPLEX applied locally next to the non-resected tumor in the brain showed a 40% survival rate at day 23 following the beginning of treatment, compared to a 0% survival rate in the standard systemic treatment arm, the placebo, and untreated control arm.
The Company plans a pre-IND Meeting with the FDA by the end of 2021 and potentially initiate a Phase 1/2 trial of OncoPLEX in brain tumors in 2022.
Price Action: PYPD shares are down 5.64% at $7.61 during the market session on the last check Monday.